Press news Biocartis Group NV: Update on Fire Incident at Biocartis Warehouse
02 August 2021 - 07:00AM
Press news Biocartis Group NV: Update on Fire Incident at Biocartis
Warehouse
PRESS RELEASE
2 August 2021, 07:00 CET
Update on Fire Incident at
Biocartis Warehouse
Mechelen,
Belgium, 2 August
2021 – Biocartis Group NV (the
‘Company’ or ‘Biocartis’) (Euronext Brussels: BCART) provides an
update regarding the impact on production and inventory following a
fire that broke out at one of the Company’s warehouse facilities in
Mechelen, Belgium, during the night of 30 July 2021.
Production Continuity
The fire caused considerable damage to the
warehouse facility. In the adjacent production facility, the
manufacturing equipment of the high-throughput ‘ML2’ cartridge
production line was not damaged but due to structural damages to
the building, and the inspections and repairs needed, production at
the ‘ML2’ line will be temporarily suspended.
Production will be transferred from the impacted
‘ML2’ production line to the ‘ML1’ production line which is located
in another building at the Mechelen site and that was not affected
by the fire. Steps have been taken to redirect additional personnel
and resources to the ‘ML1’ line and increase its output, but the
Company will be running at considerably lower manufacturing
capacity until production on ML2 can be resumed.
Inventory Update
A part of the stock of finished products and
reagents used as raw materials in Idylla™ cartridge manufacturing
was lost in the fire. However, as the Company stores inventory
across different warehouses, the stock of instruments and consoles
was not impacted and about half of the Company’s stock of finished
products is still available to meet short term demand across the
majority of the product portfolio. Also, inventory of plastic parts
was unaffected.
Raw material is available to continue cartridge
manufacturing until late August and steps will be taken the coming
days to replenish critical reagent materials from different
suppliers in order to minimize production delays.
We will be working closely with our customers
and partners to minimize the impact of these disruptions in
production and to secure serving most urgent needs.
Further updates will be made as appropriate.
--- END ---
Contact information: Jean-Marc
Roelandt Chief Financial Officer
Biocartise-mail jroelandt@biocartis.com
mobile +32 477 95 25
08
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and
sepsis. More information: www.biocartis.com. Follow us on
Twitter: @Biocartis_. Biocartis and Idylla™ are registered
trademarks in Europe, the United States and other countries. The
Biocartis and Idylla™ trademark and logo are used trademarks owned
by Biocartis. This press release is not for distribution, directly
or indirectly, in any jurisdiction where to do so would be
unlawful. Any persons reading this press release should inform
themselves of and observe any such restrictions. Biocartis takes no
responsibility for any violation of any such restrictions by any
person. Please refer to the product labeling for applicable
intended uses for each individual Biocartis product. This press
release does not constitute an offer or invitation for the sale or
purchase of securities in any jurisdiction. No securities of
Biocartis may be offered or sold in the United States of America
absent registration with the United States Securities and Exchange
Commission or an exemption from registration under the U.S.
Securities Act of 1933, as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2023 bis Mär 2024